{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T13:11:47Z","timestamp":1773493907543,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI027757"],"award-info":[{"award-number":["AI027757"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI027757"],"award-info":[{"award-number":["AI027757"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    HIV remains a significant public health challenge in Nigeria. Pre-exposure prophylaxis (PrEP) effectively prevents HIV, but uptake is hindered by stigma, limited clinic access, and provider shortages. Community pharmacies could expand access, but their role in PrEP delivery remains underexplored. We assessed Nigerian community pharmacists\u2019 willingness and support needs for delivering pharmacy-delivered oral PrEP, examined association between sociodemographic factors and willingness, and compared pharmacy geolocations with sex worker hotspots and hospitals providing PrEP. A descriptive cross-sectional survey was conducted among licensed community pharmacists in Abuja and Lagos. Data collection was conducted using a hybrid approach (on-line and on-site) over two months from January to March 2025. Associations between sociodemographic factors and willingness to provide PrEP were examined using chi-square and Fisher\u2019s exact tests. ArcGIS distance analysis compared pharmacy geolocations with sex worker hotspots and hospitals offering PrEP. Of 267 pharmacists, 99.6% expressed willingness to deliver PrEP. Key support needs included PrEP guidelines training (92.1%), access to HIV rapid tests (81.3%), counseling skills (70.8%), and logistical support (70.8%). Structural readiness was high, with significant gender differences in willingness to serve gay, bisexual, and men who have sex with men (male: 85.6% vs. female: 67.3%; \u03c7\n                    <jats:sup>2<\/jats:sup>\n                    (1) = 0.22,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.001). In Abuja and Lagos, 82.5% and 93.5% of key population hotspots, respectively, were closer to pharmacies than hospitals (\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.0001). Nigerian pharmacists are highly willing to provide PrEP. Training, particularly in gender-sensitive stigma reduction, and logistical support are essential for successful implementation.\n                  <\/jats:p>","DOI":"10.1007\/s10461-025-04923-4","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T09:50:46Z","timestamp":1760781046000},"page":"778-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expanding HIV Prevention: Exploring Community Pharmacists\u2019 Willingness to Provide PrEP in Nigeria"],"prefix":"10.1007","volume":"30","author":[{"given":"Theodora C.","family":"Omenoba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugochi","family":"Eyong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentine","family":"Okelu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Nauta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarachi","family":"Nwafor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambrose","family":"Eze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chimezie","family":"Anyakora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obinna I.","family":"Ekwunife","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"4923_CR1","unstructured":"UNAIDS. country factsheets: Nigeria-HIV and AIDS estimates [Internet]. 2023 [cited 2024 Dec 18]. Available from: https:\/\/www.unaids.org\/en\/regionscountries\/countries\/nigeria."},{"key":"4923_CR2","unstructured":"NACA, Nigeria HIVAIDS. Indicator and Impact Survey: National Summary Sheet [Internet]. Abuja: National Agency for the Control of AIDS; 2018 [cited 2025 Aug 14]. Available from: https:\/\/naca.gov.ng\/wp-content\/uploads\/2021\/02\/NAIIS-PA-NATIONAL-FACTSHEET-FINAL.pdf?utm_."},{"issue":"47","key":"4923_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.15585\/mmwr.mm7347a3","volume":"73","author":"ME Peck","year":"2024","unstructured":"Peck ME, Davis S, Odoyo-June E, Mwangi J, Oyugi E, Hoang T, et al. Progress toward UNAIDS global HIV pre-exposure prophylaxis targets: CDC-supported oral pre-exposure prophylaxis\u201437 countries, 2017\u20132023. MMWR Morb Mortal Wkly Rep. 2024;73(47):1082\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10013","key":"4923_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet Lond Engl. 2016;387(10013):53\u201360.","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"4923_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410. https:\/\/doi.org\/10.1056\/NEJMoa1108524.","journal-title":"N Engl J Med"},{"issue":"27","key":"4923_CR6","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1011205.","journal-title":"N Engl J Med"},{"key":"4923_CR7","unstructured":"Food US, Drug Administration F. FDA Approves first injectable treatment for HIV Pre\u2009=\u2009Exposure Prevention. 2021 [cited 2025 Feb 4]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention#:~:text=Today%2C%20the%20U.S.%20Food%20and%20Drug%20Administration%20approved,to%20reduce%20the%20risk%20of%20sexually%20acquired%20HIV."},{"issue":"11","key":"4923_CR8","doi-asserted-by":"publisher","first-page":"e788","DOI":"10.1016\/S2352-3018(19)30238-3","volume":"6","author":"LE Coelho","year":"2019","unstructured":"Coelho LE, Torres TS, Veloso VG, Landovitz RJ, Grinsztejn B. Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV. 2019;6(11):e788\u201399.","journal-title":"Lancet HIV"},{"issue":"4","key":"4923_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/COH.0000000000000735","volume":"17","author":"C Flexner","year":"2022","unstructured":"Flexner C. The future of long-acting agents for preexposure prophylaxis. Curr Opin HIV AIDS. 2022;17(4):192\u20138.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"4923_CR10","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1186\/s12889-023-16382-4","volume":"23","author":"BG Rogers","year":"2023","unstructured":"Rogers BG, Chan PA, Sutten-Coats C, Zanowick-Marr A, Patel RR, Mena L, et al. Perspectives on long-acting formulations of pre-exposure prophylaxis (PrEP) among men who have sex with men who are non-adherent to daily oral PrEP in the united States. BMC Public Health. 2023;23(1):1643. https:\/\/doi.org\/10.1186\/s12889-023-16382-4.","journal-title":"BMC Public Health"},{"issue":"8","key":"4923_CR11","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1007\/s10461-023-03986-5","volume":"27","author":"LT Dean","year":"2023","unstructured":"Dean LT, Predmore Z, Skinner A, Napoleon S, Chan PA, Raifman J. Optimizing uptake of long-acting injectable pre-exposure prophylaxis for HIV prevention for men who have sex with men. AIDS Behav. 2023;27(8):2606\u201316. https:\/\/doi.org\/10.1007\/s10461-023-03986-5.","journal-title":"AIDS Behav"},{"issue":"Suppl 4","key":"4923_CR12","doi-asserted-by":"publisher","first-page":"S541","DOI":"10.1093\/cid\/ciac716","volume":"75","author":"SE Cooper","year":"2022","unstructured":"Cooper SE, Rosenblatt J, Gulick RM. Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries. Clin Infect Dis Off Publ Infect Dis Soc Am. 2022;75(Suppl 4):S541\u20138.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"5","key":"4923_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/09564624231220099","volume":"35","author":"BO Olakunde","year":"2024","unstructured":"Olakunde BO, Ujam C, Ndukwe CD, Falola-Anoemuah Y, Olaifa Y, Oladele TT, et al. Barriers to the uptake of oral pre-exposure prophylaxis among young key populations in Nigeria. Int J STD AIDS. 2024;35(5):346\u201351.","journal-title":"Int J STD AIDS"},{"issue":"8","key":"4923_CR14","doi-asserted-by":"publisher","first-page":"e1002099","DOI":"10.1371\/journal.pmed.1002099","volume":"13","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to hiv-1-serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLoS Med. 2016;13(8):e1002099.","journal-title":"PLoS Med"},{"issue":"1","key":"4923_CR15","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1186\/s12913-018-3343-z","volume":"18","author":"C Mayora","year":"2018","unstructured":"Mayora C, Kitutu FE, Kandala NB, Ekirapa-Kiracho E, Peterson SS, Wamani H. Private retail drug shops: what they are, how they operate, and implications for health care delivery in rural Uganda. BMC Health Serv Res. 2018;18(1):532.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"4923_CR16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/j.1365-3156.2011.02821.x","volume":"16","author":"O Onwujekwe","year":"2011","unstructured":"Onwujekwe O, Hanson K, Uzochukwu B. Do poor people use poor quality providers? Evidence from the treatment of presumptive malaria in Nigeria. Trop Med Int Health TM IH. 2011;16(9):1087\u201398.","journal-title":"Trop Med Int Health TM IH"},{"issue":"1","key":"4923_CR17","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1186\/s12913-020-05898-9","volume":"20","author":"KF Ortblad","year":"2020","unstructured":"Ortblad KF, Mogere P, Roche S, Kamolloh K, Odoyo J, Irungu E, et al. Design of a care pathway for pharmacy-based PrEP delivery in kenya: results from a collaborative stakeholder consultation. BMC Health Serv Res. 2020;20(1):1034.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"4923_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1071\/SH18084","volume":"15","author":"EL Tung","year":"2018","unstructured":"Tung EL, Thomas A, Eichner A, Shalit P. Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care. Sex Health. 2018;15(6):556\u201361.","journal-title":"Sex Health"},{"issue":"1","key":"4923_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.japh.2019.06.021","volume":"60","author":"MI Lopez","year":"2020","unstructured":"Lopez MI, Cocohoba J, Cohen SE, Trainor N, Levy MM, Dong BJ. Implementation of pre-exposure prophylaxis at a community pharmacy through a collaborative practice agreement with San Francisco department of public health. J Am Pharm Assoc JAPhA. 2020;60(1):138\u201344.","journal-title":"J Am Pharm Assoc JAPhA"},{"key":"4923_CR20","doi-asserted-by":"crossref","unstructured":"Folayan MO, Aliyu S, Oginni A, Ezechi O, Kolawole G, Ezeama N et al. Effectiveness of three delivery models for promoting access to pre-exposure prophylaxis in HIV-1 serodiscordant couples in Nigeria. Price MA, editor. PLoS ONE. 2022;17(5):e0268011.","DOI":"10.1371\/journal.pone.0268011"},{"issue":"4","key":"4923_CR21","doi-asserted-by":"publisher","first-page":"594","DOI":"10.9745\/GHSP-D-16-00197","volume":"4","author":"M Corroon","year":"2016","unstructured":"Corroon M, Kebede E, Spektor G, Speizer I. Key role of drug shops and pharmacies for family planning in urban Nigeria and Kenya. Glob Health Sci Pract. 2016;4(4):594\u2013609.","journal-title":"Glob Health Sci Pract"},{"issue":"1","key":"4923_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12960-021-00602-2","volume":"19","author":"BO Daini","year":"2021","unstructured":"Daini BO, Okafor E, Baruwa S, Adeyanju O, Diallo R, Anyanti J. Characterization and distribution of medicine vendors in 2 States in nigeria: implications for scaling health workforce and family planning services. Hum Resour Health. 2021;19(1):60.","journal-title":"Hum Resour Health"},{"issue":"1","key":"4923_CR23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1186\/s12913-022-08503-3","volume":"22","author":"FM OlaOlorun","year":"2022","unstructured":"OlaOlorun FM, Jain A, Olalere E, Daniel-Ebune E, Afolabi K, Okafor E, et al. Nigerian stakeholders\u2019 perceptions of a pilot tier accreditation system for patent and proprietary medicine vendors to expand access to family planning services. BMC Health Serv Res. 2022;22(1):1119. https:\/\/doi.org\/10.1186\/s12913-022-08503-3.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"4923_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/sextrans-2023-056067","volume":"101","author":"F Emmanuel","year":"2025","unstructured":"Emmanuel F, Ejeckam CC, Green K, Adesina AA, Aliyu G, Ashefor G, et al. HIV epidemic among key populations in nigeria: results of the integrated biological and behavioural surveillance survey (IBBSS), 2020\u20132021. Sex Transm Infect. 2025;101(1):10\u20136.","journal-title":"Sex Transm Infect"},{"issue":"4","key":"4923_CR25","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/j.japh.2020.01.026","volume":"60","author":"MI Lopez","year":"2020","unstructured":"Lopez MI, Grant RM, Dong BJ. Community pharmacy delivered PrEP to STOP HIV transmission: an opportunity NOT to miss! J Am Pharm Assoc. 2020;60(4):e18\u201324.","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"4923_CR26","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1186\/s12913-024-12107-4","volume":"24","author":"OI Ekwunife","year":"2024","unstructured":"Ekwunife OI, Omenoba TC, Eyong U, Okelu V, Alagbile M, Ume I, et al. Collaborative design of a care pathway for pharmacy-based PrEP delivery in nigeria: insights from stakeholder consultation. BMC Health Serv Res. 2024;24(1):1621. https:\/\/doi.org\/10.1186\/s12913-024-12107-4.","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"4923_CR27","doi-asserted-by":"publisher","first-page":"e0207372","DOI":"10.1371\/journal.pone.0207372","volume":"13","author":"JM Broekhuis","year":"2018","unstructured":"Broekhuis JM, Scarsi KK, Sayles HR, Klepser DG, Havens JP, Swindells S, et al. Midwest pharmacists\u2019 familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV. PLoS ONE. 2018;13(11):e0207372.","journal-title":"PLoS ONE"},{"issue":"8","key":"4923_CR28","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/0956462415589896","volume":"27","author":"D Yoong","year":"2016","unstructured":"Yoong D, Naccarato M, Sharma M, Wilton J, Senn H, Tan DH. Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis. Int J STD AIDS. 2016;27(8):608\u201316.","journal-title":"Int J STD AIDS"},{"issue":"4","key":"4923_CR29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.japh.2018.04.007","volume":"58","author":"O Okoro","year":"2018","unstructured":"Okoro O, Hillman L. HIV pre-exposure prophylaxis: exploring the potential for expanding the role of pharmacists in public health. J Am Pharm Assoc. 2018;58(4):412\u2013e4203.","journal-title":"J Am Pharm Assoc"},{"issue":"2","key":"4923_CR30","doi-asserted-by":"publisher","first-page":"e25623","DOI":"10.2196\/25623","volume":"7","author":"J Lo","year":"2021","unstructured":"Lo J, Nwafor SU, Schwitters AM, Mitchell A, Sebastian V, Stafford KA, et al. Key population hotspots in Nigeria for targeted HIV program planning: mapping, validation, and reconciliation. JMIR Public Health Surveill. 2021;7(2):e25623.","journal-title":"JMIR Public Health Surveill"},{"key":"4923_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40545-018-0147-9","volume":"11","author":"A Ekpenyong","year":"2018","unstructured":"Ekpenyong A, Udoh A, Kpokiri E, Bates I. An analysis of pharmacy workforce capacity in Nigeria. J Pharm Policy Pract. 2018;11:20.","journal-title":"J Pharm Policy Pract"},{"key":"4923_CR32","unstructured":"Pharmacists Council of Nigeria. Pharmacists Council of Nigeria: About [Internet]. [cited 2025 Apr 12]. Available from: https:\/\/pcn.gov.ng\/registrations\/licensing\/."},{"issue":"3","key":"4923_CR33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.5964\/ejop.v16i3.3107","volume":"16","author":"M Bosnjak","year":"2020","unstructured":"Bosnjak M, Ajzen I, Schmidt P. The theory of planned behavior: selected recent advances and applications. Eur J Psychol. 2020;16(3):352\u20136.","journal-title":"Eur J Psychol"},{"issue":"6","key":"4923_CR34","doi-asserted-by":"publisher","first-page":"e26131","DOI":"10.1002\/jia2.26131","volume":"26","author":"KF Ortblad","year":"2023","unstructured":"Ortblad KF, Mogere P, Omollo V, Kuo AP, Asewe M, Gakuo S, et al. Stand-alone model for delivery of oral HIV pre\u2010exposure prophylaxis in kenya: a single\u2010arm, prospective pilot evaluation. J Int AIDS Soc. 2023;26(6):e26131.","journal-title":"J Int AIDS Soc"},{"key":"4923_CR35","unstructured":"Institute of Human Virology, Nigeria (IHVN). IHVN Supported PrEP Facilities. 2025 [cited 2025 Mar 4]. Available from: https:\/\/wpad.ihvnigeria.org\/faq-about-prep\/."},{"key":"4923_CR36","unstructured":"National Agency for the Control of AIDS (NACA). NATIONAL HIV SELF-TESTING (HIVST) AND PRE-EXPOSURE PROPHYLAXIS (PREP). 2022 [cited 2025 Apr 3]; Available from: https:\/\/naca.gov.ng\/national-hiv-self-testing-hivst-and-pre-exposure-prophylaxis-prep\/."},{"issue":"8","key":"4923_CR37","doi-asserted-by":"publisher","first-page":"e103619","DOI":"10.1371\/journal.pone.0103619","volume":"9","author":"A Ikpeazu","year":"2014","unstructured":"Ikpeazu A, Momah-Haruna A, Madu Mari B, Thompson LH, Ogungbemi K, Daniel U, et al. An appraisal of female sex work in Nigeria\u2014implications for designing and scaling up HIV prevention programmes. PLoS ONE. 2014;9(8):e103619.","journal-title":"PLoS ONE"},{"key":"4923_CR38","unstructured":"Onnaedo. 5 streets in Lagos that NEVER sleep | Pulse Nigeria [Internet]. [cited 2025 Aug 12]. Available from: https:\/\/www.pulse.ng\/articles\/lifestyle\/food-and-travel\/5-streets-in-lagos-that-never-sleep-2024080506213742129."},{"key":"4923_CR39","unstructured":"Nairaland FIVE. Most Popular Commercial Sex Zones In Abuja - Romance - Nigeria [Internet]. [cited 2025 Aug 12]. Available from: https:\/\/www.nairaland.com\/2761636\/five-most-popular-commercial-sex."},{"key":"4923_CR40","unstructured":"Rhema. Top 7 Strip Clubs in Abuja [Internet]. YonneTours. 2025 [cited 2025 Aug 12]. Available from: https:\/\/yonnetours.com\/top-strip-clubs-in-abuja\/."},{"issue":"1","key":"4923_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.japh.2020.10.005","volume":"61","author":"R Hopkins","year":"2021","unstructured":"Hopkins R, Josma D, Morris J, Klepser DG, Young HN, Crawford ND. Support and perceived barriers to implementing pre-exposure prophylaxis screening and dispensing in pharmacies: examining concordance between pharmacy technicians and pharmacists. J Am Pharm Assoc. 2021;61(1):115\u201320.","journal-title":"J Am Pharm Assoc"},{"issue":"6","key":"4923_CR42","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.japh.2020.06.005","volume":"60","author":"KA Koester","year":"2020","unstructured":"Koester KA, Saberi P, Fuller SM, Arnold EA, Steward WT. Attitudes about community pharmacy access to HIV prevention medications in California. J Am Pharm Assoc. 2020;60(6):e179\u201383.","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"4923_CR43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12879-019-3713-0","volume":"19","author":"JKB Matovu","year":"2019","unstructured":"Matovu JKB, Musinguzi G, Kiguli J, Nuwaha F, Mujisha G, Musinguzi J, et al. Health providers\u2019 experiences, perceptions and readiness to provide HIV services to men who have sex with men and female sex workers in Uganda\u2014a qualitative study. BMC Infect Dis. 2019;19(1):214.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"4923_CR44","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.japh.2019.12.003","volume":"60","author":"ND Crawford","year":"2020","unstructured":"Crawford ND, Josma D, Morris J, Hopkins R, Young HN. Pharmacy-based pre-exposure prophylaxis support among pharmacists and men who have sex with men. J Am Pharm Assoc. 2020;60(4):602\u20138.","journal-title":"J Am Pharm Assoc"},{"issue":"6","key":"4923_CR45","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.japh.2020.03.013","volume":"60","author":"V Zhu","year":"2020","unstructured":"Zhu V, Tran D, Banjo O, Onuegbu R, Seung H, Layson-Wolf C. Patient perception of community pharmacists prescribing pre-exposure prophylaxis for HIV prevention. J Am Pharm Assoc. 2020;60(6):781\u2013e7882.","journal-title":"J Am Pharm Assoc"},{"key":"4923_CR46","unstructured":"NASTAD, Legislative Tracker. Pharmacist-Initiated PrEP and PEP. 2024 [cited 2025 Apr 23]; Available from: https:\/\/nastad.org\/resources\/pharmacist-initiated-prep-and-pep-2024."},{"issue":"6","key":"4923_CR47","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11904-021-00578-7","volume":"18","author":"E Rousseau","year":"2021","unstructured":"Rousseau E, Julies RF, Madubela N, Kassim S. Novel platforms for biomedical HIV prevention delivery to key populations - community mobile clinics, peer-supported, pharmacy-led PrEP delivery, and the use of telemedicine. Curr HIV\/AIDS Rep. 2021;18(6):500\u20137.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"4923_CR48","doi-asserted-by":"publisher","first-page":"232595822312158","DOI":"10.1177\/23259582231215882","volume":"22","author":"M Vera","year":"2023","unstructured":"Vera M, Bukusi E, Achieng P, Aketch H, Araka E, Baeten JM, et al. Pharmacies are Everywhere, and you can get it at any time: experiences with pharmacy-based PrEP delivery among adolescent girls and young women in Kisumu, Kenya. J Int Assoc Provid AIDS Care JIAPAC. 2023;22:23259582231215882. https:\/\/doi.org\/10.1177\/23259582231215882.","journal-title":"J Int Assoc Provid AIDS Care JIAPAC"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04923-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-025-04923-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04923-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T11:50:22Z","timestamp":1773489022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-025-04923-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4923"],"URL":"https:\/\/doi.org\/10.1007\/s10461-025-04923-4","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"21 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval for the study was obtained from the Federal Capital Territory Health Research Ethics Committee (HREC) with approval number FHREC\/2025\/01\/02\/08-01-25.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All participants provided informed consent before participation. Participation was voluntary, and confidentiality was maintained throughout the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}